 Isaac Teitelbaum
Concepts (359)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Dialysis | 59 | 2025 | 100 | 15.300 |
Why?
| | Kidney Failure, Chronic | 45 | 2025 | 598 | 8.520 |
Why?
| | Peritonitis | 23 | 2025 | 84 | 4.480 |
Why?
| | Dialysis Solutions | 12 | 2025 | 23 | 2.600 |
Why?
| | Renal Dialysis | 18 | 2022 | 462 | 2.270 |
Why?
| | Hyponatremia | 3 | 2025 | 43 | 1.800 |
Why?
| | Sodium | 4 | 2025 | 197 | 1.770 |
Why?
| | Glucans | 3 | 2025 | 22 | 1.370 |
Why?
| | Peritoneum | 6 | 2023 | 45 | 1.090 |
Why?
| | Kidney | 8 | 2023 | 1495 | 1.070 |
Why?
| | Glucose | 3 | 2025 | 1047 | 0.940 |
Why?
| | Serum Albumin | 3 | 2022 | 147 | 0.840 |
Why?
| | Kidney Tubules, Collecting | 12 | 1994 | 27 | 0.830 |
Why?
| | Peritoneal Dialysis, Continuous Ambulatory | 7 | 2025 | 16 | 0.740 |
Why?
| | Catheters, Indwelling | 5 | 2019 | 96 | 0.670 |
Why?
| | Staphylococcus capitis | 1 | 2019 | 1 | 0.620 |
Why?
| | Acute Kidney Injury | 5 | 2023 | 865 | 0.620 |
Why?
| | Coagulase | 1 | 2019 | 6 | 0.620 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2015 | 653 | 0.590 |
Why?
| | Renal Replacement Therapy | 4 | 2023 | 100 | 0.580 |
Why?
| | Ferric Compounds | 2 | 2022 | 55 | 0.580 |
Why?
| | Sucrose | 2 | 2022 | 112 | 0.570 |
Why?
| | Catheter-Related Infections | 1 | 2019 | 94 | 0.570 |
Why?
| | Quality of Health Care | 2 | 2020 | 691 | 0.560 |
Why?
| | Humans | 81 | 2025 | 144759 | 0.550 |
Why?
| | Hyperphosphatemia | 3 | 2022 | 15 | 0.530 |
Why?
| | Arginine Vasopressin | 7 | 1997 | 44 | 0.530 |
Why?
| | Kidney Transplantation | 3 | 2012 | 704 | 0.530 |
Why?
| | Anti-Bacterial Agents | 6 | 2024 | 1907 | 0.520 |
Why?
| | Staphylococcal Infections | 3 | 2019 | 388 | 0.510 |
Why?
| | Peritoneal Fibrosis | 1 | 2017 | 2 | 0.510 |
Why?
| | Kidney Function Tests | 4 | 2020 | 157 | 0.490 |
Why?
| | Uremia | 2 | 2014 | 15 | 0.490 |
Why?
| | Patient-Centered Care | 1 | 2020 | 544 | 0.460 |
Why?
| | Therapeutics | 1 | 2015 | 13 | 0.440 |
Why?
| | Kidney Medulla | 10 | 1997 | 31 | 0.440 |
Why?
| | Body Water | 1 | 2015 | 23 | 0.440 |
Why?
| | Voriconazole | 1 | 2015 | 21 | 0.440 |
Why?
| | beta-Cyclodextrins | 1 | 2015 | 32 | 0.440 |
Why?
| | Phosphates | 2 | 2022 | 180 | 0.420 |
Why?
| | Catheterization | 3 | 2016 | 183 | 0.420 |
Why?
| | Antifungal Agents | 1 | 2015 | 149 | 0.410 |
Why?
| | Chelating Agents | 1 | 2014 | 71 | 0.400 |
Why?
| | Blood Pressure | 1 | 2020 | 1769 | 0.390 |
Why?
| | GTP-Binding Proteins | 6 | 1995 | 153 | 0.370 |
Why?
| | Type C Phospholipases | 6 | 1992 | 69 | 0.370 |
Why?
| | Hemodialysis Solutions | 1 | 2012 | 3 | 0.370 |
Why?
| | Acidosis | 1 | 2013 | 105 | 0.350 |
Why?
| | Kidney Diseases | 4 | 2021 | 427 | 0.350 |
Why?
| | Hemofiltration | 2 | 2010 | 24 | 0.340 |
Why?
| | Hirudins | 1 | 2010 | 51 | 0.320 |
Why?
| | Practice Patterns, Physicians' | 3 | 2025 | 1356 | 0.320 |
Why?
| | Cyclic AMP | 6 | 1995 | 209 | 0.310 |
Why?
| | Urea | 4 | 2021 | 84 | 0.300 |
Why?
| | Creatinine | 5 | 2020 | 506 | 0.300 |
Why?
| | Middle Aged | 21 | 2025 | 35875 | 0.300 |
Why?
| | Protein Kinase C | 5 | 1995 | 252 | 0.300 |
Why?
| | Heparin | 1 | 2010 | 244 | 0.290 |
Why?
| | Kidney Tubules | 4 | 1990 | 117 | 0.290 |
Why?
| | Nutritional Status | 4 | 2022 | 354 | 0.280 |
Why?
| | Heart Diseases | 1 | 2012 | 349 | 0.280 |
Why?
| | Glomerular Filtration Rate | 5 | 2023 | 760 | 0.280 |
Why?
| | Drug Resistance, Bacterial | 1 | 2009 | 196 | 0.270 |
Why?
| | Hemodialysis, Home | 4 | 2023 | 9 | 0.270 |
Why?
| | Peptide Fragments | 1 | 2010 | 699 | 0.250 |
Why?
| | Survivors | 1 | 2010 | 520 | 0.240 |
Why?
| | Prospective Studies | 12 | 2025 | 7990 | 0.240 |
Why?
| | Scleroderma, Systemic | 1 | 2007 | 123 | 0.240 |
Why?
| | Calcium | 4 | 2020 | 1183 | 0.230 |
Why?
| | Patient Selection | 2 | 2020 | 719 | 0.230 |
Why?
| | Cardiac Surgical Procedures | 1 | 2012 | 609 | 0.230 |
Why?
| | Hernia, Abdominal | 1 | 2005 | 8 | 0.230 |
Why?
| | Peritoneal Cavity | 1 | 2005 | 30 | 0.230 |
Why?
| | Patient Participation | 2 | 2020 | 431 | 0.220 |
Why?
| | Postoperative Complications | 3 | 2012 | 2919 | 0.220 |
Why?
| | Female | 25 | 2025 | 78271 | 0.220 |
Why?
| | Phosphorus | 3 | 2022 | 99 | 0.220 |
Why?
| | Liver Transplantation | 2 | 2012 | 823 | 0.210 |
Why?
| | Liver Failure | 1 | 2005 | 83 | 0.210 |
Why?
| | Aged | 15 | 2025 | 25913 | 0.210 |
Why?
| | Internationality | 3 | 2020 | 156 | 0.210 |
Why?
| | Hemoglobins | 2 | 2020 | 384 | 0.210 |
Why?
| | Time Factors | 6 | 2015 | 7173 | 0.210 |
Why?
| | Teicoplanin | 1 | 2024 | 14 | 0.200 |
Why?
| | Male | 25 | 2025 | 72315 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2025 | 2027 | 0.200 |
Why?
| | Quality Improvement | 2 | 2023 | 1289 | 0.190 |
Why?
| | Blood Chemical Analysis | 1 | 2003 | 109 | 0.190 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1560 | 0.180 |
Why?
| | Quality of Life | 5 | 2020 | 3185 | 0.180 |
Why?
| | Phosphatidylinositols | 3 | 1991 | 57 | 0.180 |
Why?
| | Device Removal | 2 | 2019 | 143 | 0.180 |
Why?
| | Rats | 13 | 2014 | 5597 | 0.180 |
Why?
| | Contraindications, Procedure | 1 | 2021 | 12 | 0.180 |
Why?
| | Treatment Outcome | 10 | 2025 | 11679 | 0.170 |
Why?
| | Goals | 2 | 2020 | 183 | 0.170 |
Why?
| | Nephrologists | 1 | 2021 | 14 | 0.170 |
Why?
| | Attitude of Health Personnel | 2 | 2020 | 1185 | 0.170 |
Why?
| | Organism Hydration Status | 1 | 2020 | 9 | 0.170 |
Why?
| | Superior Vena Cava Syndrome | 1 | 2000 | 4 | 0.170 |
Why?
| | Chylous Ascites | 1 | 2000 | 5 | 0.160 |
Why?
| | Liposomes | 1 | 2022 | 250 | 0.160 |
Why?
| | Epidermal Growth Factor | 6 | 1994 | 171 | 0.160 |
Why?
| | Liver Cirrhosis | 1 | 2003 | 288 | 0.160 |
Why?
| | Acid-Base Equilibrium | 1 | 2020 | 24 | 0.160 |
Why?
| | Critical Illness | 4 | 2023 | 891 | 0.160 |
Why?
| | Blood Volume | 1 | 2020 | 65 | 0.160 |
Why?
| | Stress, Psychological | 1 | 2009 | 1152 | 0.160 |
Why?
| | Risk Factors | 7 | 2023 | 10779 | 0.160 |
Why?
| | Magnesium | 1 | 2020 | 155 | 0.150 |
Why?
| | Potassium | 1 | 2020 | 152 | 0.150 |
Why?
| | Cohort Studies | 5 | 2025 | 5960 | 0.150 |
Why?
| | Patient Care Planning | 1 | 2020 | 169 | 0.150 |
Why?
| | Physician Executives | 1 | 2019 | 27 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 488 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2020 | 221 | 0.140 |
Why?
| | Dogs | 2 | 2023 | 437 | 0.140 |
Why?
| | Receptors, Vasopressin | 2 | 1995 | 20 | 0.130 |
Why?
| | Societies, Medical | 2 | 2020 | 887 | 0.130 |
Why?
| | Kidney Concentrating Ability | 1 | 1997 | 3 | 0.130 |
Why?
| | Drug Combinations | 2 | 2022 | 390 | 0.130 |
Why?
| | Survival Rate | 2 | 2020 | 2089 | 0.130 |
Why?
| | Renal Insufficiency | 1 | 2020 | 168 | 0.130 |
Why?
| | Data Collection | 1 | 2020 | 633 | 0.130 |
Why?
| | Adenylyl Cyclase Inhibitors | 2 | 1994 | 7 | 0.130 |
Why?
| | Patient Education as Topic | 3 | 2018 | 780 | 0.130 |
Why?
| | Adenylyl Cyclases | 3 | 1993 | 60 | 0.130 |
Why?
| | Risk Assessment | 4 | 2016 | 3671 | 0.130 |
Why?
| | Adult | 18 | 2024 | 40449 | 0.120 |
Why?
| | United States | 7 | 2023 | 15966 | 0.120 |
Why?
| | Proportional Hazards Models | 3 | 2022 | 1325 | 0.120 |
Why?
| | Survival Analysis | 2 | 2015 | 1382 | 0.120 |
Why?
| | Hormones | 2 | 1994 | 134 | 0.120 |
Why?
| | Models, Animal | 1 | 2017 | 392 | 0.110 |
Why?
| | Ultrafiltration | 1 | 2015 | 30 | 0.110 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2017 | 219 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 2 | 2015 | 965 | 0.100 |
Why?
| | Gastrointestinal Absorption | 1 | 2014 | 5 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1059 | 0.100 |
Why?
| | Diglycerides | 2 | 1993 | 59 | 0.100 |
Why?
| | Lung Injury | 1 | 2017 | 237 | 0.100 |
Why?
| | Virulence Factors, Bordetella | 2 | 1991 | 15 | 0.100 |
Why?
| | Pertussis Toxin | 2 | 1991 | 24 | 0.100 |
Why?
| | Treatment Failure | 1 | 2015 | 365 | 0.100 |
Why?
| | Biological Transport | 1 | 2015 | 417 | 0.100 |
Why?
| | Didanosine | 1 | 1993 | 13 | 0.100 |
Why?
| | Phospholipases A | 2 | 1992 | 98 | 0.100 |
Why?
| | Inflammation | 3 | 2017 | 2878 | 0.100 |
Why?
| | Anti-Infective Agents | 1 | 2016 | 242 | 0.100 |
Why?
| | Cytosol | 1 | 1994 | 227 | 0.100 |
Why?
| | Animals | 17 | 2023 | 38058 | 0.100 |
Why?
| | Biomedical Research | 1 | 2020 | 710 | 0.100 |
Why?
| | HIV Seropositivity | 1 | 1993 | 119 | 0.090 |
Why?
| | Oleanolic Acid | 1 | 2012 | 9 | 0.090 |
Why?
| | Methylene Blue | 1 | 2012 | 24 | 0.090 |
Why?
| | Equipment Design | 2 | 2014 | 530 | 0.090 |
Why?
| | Vascular Calcification | 1 | 2014 | 110 | 0.090 |
Why?
| | Tissue Adhesions | 1 | 2012 | 34 | 0.090 |
Why?
| | Palliative Care | 1 | 2020 | 1002 | 0.090 |
Why?
| | Delayed Graft Function | 1 | 2012 | 46 | 0.090 |
Why?
| | Hematinics | 1 | 2012 | 22 | 0.090 |
Why?
| | Cells, Cultured | 9 | 1994 | 4154 | 0.090 |
Why?
| | Prognosis | 4 | 2016 | 4282 | 0.090 |
Why?
| | Receptors, Angiotensin | 1 | 1991 | 11 | 0.090 |
Why?
| | Nephrectomy | 1 | 2012 | 158 | 0.090 |
Why?
| | Vasoconstrictor Agents | 1 | 2012 | 144 | 0.090 |
Why?
| | Transplantation, Homologous | 1 | 2012 | 415 | 0.090 |
Why?
| | Atrial Natriuretic Factor | 1 | 1991 | 57 | 0.080 |
Why?
| | Hypotension | 1 | 2012 | 126 | 0.080 |
Why?
| | Restless Legs Syndrome | 1 | 2011 | 20 | 0.080 |
Why?
| | Bacterial Infections | 2 | 2003 | 246 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2023 | 17066 | 0.080 |
Why?
| | Glycerides | 1 | 1990 | 17 | 0.080 |
Why?
| | Aluminum Compounds | 1 | 1990 | 6 | 0.080 |
Why?
| | Phospholipases | 1 | 1990 | 14 | 0.080 |
Why?
| | Antithrombins | 1 | 2010 | 70 | 0.080 |
Why?
| | Membranes, Artificial | 1 | 2010 | 75 | 0.080 |
Why?
| | Virginiamycin | 1 | 2009 | 3 | 0.080 |
Why?
| | Graft Survival | 1 | 2012 | 526 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2011 | 5408 | 0.080 |
Why?
| | Daptomycin | 1 | 2009 | 18 | 0.070 |
Why?
| | Oxazolidinones | 1 | 2009 | 17 | 0.070 |
Why?
| | Linezolid | 1 | 2009 | 25 | 0.070 |
Why?
| | Models, Biological | 1 | 2017 | 1821 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2012 | 2029 | 0.070 |
Why?
| | Acetamides | 1 | 2009 | 37 | 0.070 |
Why?
| | Minerals | 1 | 2009 | 47 | 0.070 |
Why?
| | Protein Kinases | 1 | 1991 | 315 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 824 | 0.070 |
Why?
| | Infection Control | 1 | 2010 | 172 | 0.070 |
Why?
| | Hematuria | 1 | 1988 | 11 | 0.070 |
Why?
| | Antibiotic Prophylaxis | 2 | 2022 | 129 | 0.070 |
Why?
| | Enzyme Activation | 4 | 1994 | 766 | 0.070 |
Why?
| | Communicable Diseases | 1 | 2010 | 163 | 0.070 |
Why?
| | Sympathetic Nervous System | 1 | 1989 | 178 | 0.070 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2007 | 26 | 0.070 |
Why?
| | Proteinuria | 1 | 1988 | 102 | 0.070 |
Why?
| | Hepatorenal Syndrome | 1 | 2007 | 15 | 0.070 |
Why?
| | Tetradecanoylphorbol Acetate | 3 | 1993 | 153 | 0.060 |
Why?
| | Spondylitis, Ankylosing | 1 | 1988 | 43 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1370 | 0.060 |
Why?
| | RNA, Messenger | 1 | 1995 | 2832 | 0.060 |
Why?
| | Sleep Wake Disorders | 1 | 2011 | 301 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2019 | 8265 | 0.060 |
Why?
| | Inositol Phosphates | 3 | 1991 | 21 | 0.060 |
Why?
| | Primary Prevention | 2 | 2016 | 220 | 0.060 |
Why?
| | ErbB Receptors | 1 | 1990 | 627 | 0.060 |
Why?
| | Biopsy, Needle | 1 | 2007 | 183 | 0.060 |
Why?
| | Hemodialysis Units, Hospital | 1 | 2005 | 5 | 0.060 |
Why?
| | Nephrology | 2 | 2020 | 60 | 0.060 |
Why?
| | Incidence | 3 | 2007 | 2879 | 0.060 |
Why?
| | Imipenem | 1 | 2005 | 16 | 0.060 |
Why?
| | Ethics, Clinical | 1 | 2005 | 9 | 0.060 |
Why?
| | Anticoagulants | 1 | 2010 | 722 | 0.060 |
Why?
| | Kinetics | 3 | 2017 | 1627 | 0.060 |
Why?
| | Skin Diseases | 1 | 2007 | 149 | 0.060 |
Why?
| | Vasculitis | 1 | 2005 | 69 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 455 | 0.050 |
Why?
| | Medication Adherence | 1 | 2009 | 539 | 0.050 |
Why?
| | Capillaries | 1 | 2005 | 124 | 0.050 |
Why?
| | Fibrosis | 1 | 2007 | 548 | 0.050 |
Why?
| | Gastric Acid | 1 | 2023 | 14 | 0.050 |
Why?
| | Canada | 1 | 2005 | 428 | 0.050 |
Why?
| | Bromcresol Green | 1 | 2003 | 1 | 0.050 |
Why?
| | Bromcresol Purple | 1 | 2003 | 1 | 0.050 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2003 | 15 | 0.050 |
Why?
| | Hepcidins | 1 | 2023 | 22 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2007 | 1266 | 0.050 |
Why?
| | Indicators and Reagents | 1 | 2003 | 106 | 0.050 |
Why?
| | Triglycerides | 1 | 2006 | 520 | 0.050 |
Why?
| | Permeability | 1 | 2003 | 168 | 0.050 |
Why?
| | Drug Resistance | 2 | 2012 | 153 | 0.050 |
Why?
| | Eosinophils | 1 | 2006 | 316 | 0.050 |
Why?
| | Equipment Failure | 1 | 2003 | 115 | 0.050 |
Why?
| | Vancomycin | 1 | 2024 | 93 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4557 | 0.050 |
Why?
| | Inositol 1,4,5-Trisphosphate | 2 | 1994 | 20 | 0.050 |
Why?
| | Monocytes | 1 | 2006 | 538 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2011 | 1098 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2011 | 2925 | 0.050 |
Why?
| | Regression Analysis | 1 | 2005 | 1003 | 0.050 |
Why?
| | Hypoalbuminemia | 1 | 2022 | 28 | 0.050 |
Why?
| | Cats | 1 | 2023 | 228 | 0.050 |
Why?
| | Medicare | 2 | 2022 | 886 | 0.050 |
Why?
| | Lung Transplantation | 1 | 2005 | 338 | 0.040 |
Why?
| | Burns | 1 | 2007 | 377 | 0.040 |
Why?
| | Ownership | 1 | 2023 | 111 | 0.040 |
Why?
| | Phospholipases A2 | 2 | 1992 | 79 | 0.040 |
Why?
| | Patient Compliance | 1 | 2006 | 588 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2023 | 323 | 0.040 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 2 | 1991 | 15 | 0.040 |
Why?
| | Guanosine Diphosphate | 2 | 1991 | 20 | 0.040 |
Why?
| | Thionucleotides | 2 | 1991 | 35 | 0.040 |
Why?
| | Erythrocytes | 1 | 2006 | 757 | 0.040 |
Why?
| | Dinoprostone | 2 | 1990 | 178 | 0.040 |
Why?
| | Recurrence | 1 | 2003 | 1135 | 0.040 |
Why?
| | Chronic Disease | 1 | 2005 | 1813 | 0.040 |
Why?
| | Child | 3 | 2013 | 22633 | 0.040 |
Why?
| | Potassium, Dietary | 1 | 1998 | 12 | 0.030 |
Why?
| | Drinking | 1 | 1998 | 42 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2020 | 255 | 0.030 |
Why?
| | Sodium, Dietary | 1 | 1998 | 37 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2115 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 2168 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2583 | 0.030 |
Why?
| | Quality Control | 1 | 2017 | 163 | 0.030 |
Why?
| | Diabetic Nephropathies | 1 | 2000 | 318 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2017 | 147 | 0.030 |
Why?
| | Hospitalization | 1 | 2006 | 2433 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2003 | 3409 | 0.030 |
Why?
| | Prostaglandins | 1 | 1995 | 94 | 0.030 |
Why?
| | Ionomycin | 1 | 1994 | 22 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 335 | 0.030 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1994 | 168 | 0.030 |
Why?
| | Isoproterenol | 1 | 1994 | 97 | 0.030 |
Why?
| | Colforsin | 1 | 1993 | 48 | 0.020 |
Why?
| | Prevalence | 2 | 2011 | 2834 | 0.020 |
Why?
| | Guanylate Cyclase | 1 | 1992 | 39 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 780 | 0.020 |
Why?
| | Shock, Surgical | 1 | 2012 | 2 | 0.020 |
Why?
| | Catecholamines | 1 | 2012 | 87 | 0.020 |
Why?
| | Intraoperative Care | 1 | 2012 | 62 | 0.020 |
Why?
| | Sample Size | 1 | 2012 | 123 | 0.020 |
Why?
| | Poisson Distribution | 1 | 2012 | 78 | 0.020 |
Why?
| | Prospective Payment System | 1 | 2011 | 15 | 0.020 |
Why?
| | Base Sequence | 1 | 1995 | 2190 | 0.020 |
Why?
| | Total Quality Management | 1 | 2011 | 57 | 0.020 |
Why?
| | Inositol | 1 | 1991 | 24 | 0.020 |
Why?
| | Receptors, Oxytocin | 1 | 1991 | 20 | 0.020 |
Why?
| | Accreditation | 1 | 2011 | 101 | 0.020 |
Why?
| | Cyclic GMP | 1 | 1991 | 92 | 0.020 |
Why?
| | Dideoxyadenosine | 1 | 1990 | 3 | 0.020 |
Why?
| | Oxytocin | 1 | 1991 | 51 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1995 | 2930 | 0.020 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1990 | 28 | 0.020 |
Why?
| | Adenosine Diphosphate Ribose | 1 | 1990 | 5 | 0.020 |
Why?
| | Isoquinolines | 1 | 1990 | 44 | 0.020 |
Why?
| | Fluorides | 1 | 1990 | 49 | 0.020 |
Why?
| | Guanosine Triphosphate | 1 | 1990 | 89 | 0.020 |
Why?
| | Aluminum | 1 | 1990 | 43 | 0.020 |
Why?
| | Hydrolysis | 1 | 1990 | 199 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 2527 | 0.020 |
Why?
| | Adrenergic alpha-Agonists | 1 | 1989 | 27 | 0.020 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 1989 | 34 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1306 | 0.020 |
Why?
| | Health Surveys | 1 | 2011 | 518 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 1989 | 321 | 0.020 |
Why?
| | Adrenergic beta-Agonists | 1 | 1989 | 92 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1990 | 1047 | 0.020 |
Why?
| | Glomerulonephritis, IGA | 1 | 1988 | 12 | 0.020 |
Why?
| | Piperazines | 1 | 1990 | 381 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1989 | 250 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1053 | 0.020 |
Why?
| | Cost of Illness | 1 | 2009 | 321 | 0.020 |
Why?
| | Morbidity | 1 | 2007 | 323 | 0.010 |
Why?
| | Research Design | 1 | 2012 | 1135 | 0.010 |
Why?
| | Cilastatin | 1 | 2005 | 2 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2009 | 395 | 0.010 |
Why?
| | Hemodiafiltration | 1 | 2005 | 7 | 0.010 |
Why?
| | Biomarkers | 1 | 2017 | 4271 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1539 | 0.010 |
Why?
| | Osmolar Concentration | 2 | 1998 | 167 | 0.010 |
Why?
| | Healthcare Disparities | 1 | 2012 | 727 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 2005 | 102 | 0.010 |
Why?
| | Biopsy | 1 | 1988 | 1075 | 0.010 |
Why?
| | Telemedicine | 1 | 2014 | 945 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1985 | 0.010 |
Why?
| | Comorbidity | 1 | 2009 | 1658 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 1030 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 1990 | 969 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2005 | 547 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 1047 | 0.010 |
Why?
| | Graft Rejection | 1 | 2005 | 540 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 846 | 0.010 |
Why?
| | Colorado | 1 | 1990 | 4564 | 0.010 |
Why?
| | Mice | 1 | 2017 | 18339 | 0.010 |
Why?
| | Lung Diseases | 1 | 2005 | 787 | 0.010 |
Why?
| | Diet, Vegetarian | 1 | 1998 | 10 | 0.010 |
Why?
| | Beer | 1 | 1998 | 13 | 0.010 |
Why?
| | Urine | 1 | 1998 | 62 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 5868 | 0.010 |
Why?
| | Dietary Proteins | 1 | 1998 | 136 | 0.010 |
Why?
| | Signal Transduction | 1 | 1990 | 5226 | 0.010 |
Why?
| | Muscarine | 1 | 1994 | 3 | 0.010 |
Why?
| | Carbachol | 1 | 1994 | 17 | 0.010 |
Why?
| | Vasopressins | 1 | 1994 | 60 | 0.010 |
Why?
| | Tyrosine | 1 | 1994 | 222 | 0.010 |
Why?
| | Cell Polarity | 1 | 1994 | 137 | 0.010 |
Why?
| | Purines | 1 | 1994 | 187 | 0.010 |
Why?
| | Adolescent | 1 | 2012 | 22428 | 0.010 |
Why?
| | Lung | 1 | 2005 | 4109 | 0.010 |
Why?
| | Hypertonic Solutions | 1 | 1991 | 7 | 0.010 |
Why?
| | Nocodazole | 1 | 1991 | 17 | 0.010 |
Why?
| | Cycloheximide | 1 | 1991 | 46 | 0.010 |
Why?
| | Isotonic Solutions | 1 | 1991 | 39 | 0.010 |
Why?
| | Culture Media | 1 | 1991 | 161 | 0.010 |
Why?
| | Phosphorylation | 1 | 1994 | 1732 | 0.000 |
Why?
| | Peptides | 1 | 1994 | 995 | 0.000 |
Why?
|
|
Teitelbaum's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|